Spondyloarthritis & psoriatic arthritis
Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial
Authors' conclusion
While both composite and global outcome measurement instruments performed well in pSpA, composite scores like DAPSA, ASDAS and BASDAI showed better construct validity. The clinical remission definition was the most discriminatory response criterion.
Study context
- Population
- Patients with early active peripheral spondyloarthritis (pSpA)
- Participants
- 60 patients
- Comparison
- Disease activity instruments and response criteria in pSpA
- Golimumab (GOL)n = 40
- Placebo (PBO)n = 20reference
- Primary endpoint
- Construct validity (known group discrimination, SMD), longitudinal construct validity (standardised response mean, effect size) and trial discrimination (SMD; χ2 test for binary outcomes) of disease activity instruments
- Follow-up
- Week 12
Methodological detailspost-hoc analysis, placebo-controlled, measurement properties study
- Post-hoc analysis
- Placebo-controlled
- Measurement properties study
Primary result
As reported in the abstract
- Construct validity better for composite outcomes (Disease Activity in Psoriatic Arthritis (DAPSA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Axial Spondyloarthritis Disease Activity Score (ASDAS)): higher SMD between active and inactive patients
- Longitudinal construct validity consistently good for composite outcomes (eg, ASDAS, DAPSA) and global assessments (Patient Global Assessment (PGA), Physician Global Assessment (PhGA))
- Trial discrimination good for composites (BASDAI, ASDAS, DAPSA), global assessments (PGA, PhGA) and joint counts (swollen joint count (SJC66), tender joint count (TJC68))
- Among binary outcomes, trial discrimination strongest for clinical remission (absence of arthritis, enthesitis and dactylitis), BASDAI50, DAPSA-LDA and ASDAS-LDA
- Post-hoc analysis
Original publication
Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial. RMD Open. Published 15 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →